HCV Direct Acting Antiviral Market Overview 2030
Hepatitis C is a viral infection that causes inflammation of the liver, which can lead to severe liver damage. Infections caused by the blood-borne virus hepatitis C virus (HCV) are spread through contaminated blood. There is improvement in the management of patients suffering from HCA infections and the patients can be easily treated with the use of oral medication. This treatment will last for two to six months, depending on the patient’s improvement and the recommendations of the healthcare provider. Hepatitis C is one of the main causes of liver cancer.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the HCV direct acting antiviral market.
Top Impacting Factors
- Rise in cases of liver diseases, increase in incidence of hospital acquired infection across the globe, surge in prevalence of infectious diseases, rise in demand of early diagnosis of chronic infectious diseases, surge in geriatric population, and lack of sanitization practices are the key factors that drive the growth of the HCV direct acting antiviral market.
- In addition, rise in demand of advance healthcare services, increase in investments on healthcare sector, surge in adoption of unhealthy lifestyle, increase in usage of personalized medication procedures, rise in usage of oral antiviral medications, and increase in usage of minimally invasive hepatitis C treatment procedures are some factors that fuel the growth of the HCV direct acting antiviral market.
- However, severe adverse effects related use of anti-viral drugs hinder the growth of the market.
- Contrarily, government initiatives to spread awareness regarding treatment of hepatitis C treatment and fast track regulatory approvals for novel drugs are expected to offer lucrative opportunities for the expansion of the HCV direct acting antiviral market.
Market Trends
New Product Launches to Flourish the Market
In 2020, Gilead announced launch of Hepatitis C antiviral VOSEVI drug in China. This drug is a direct acting antiviral drug which can be used in treatment of mild to severe hepatitis C infection.
In 2019, AbbVie announced approval of U.S. Food and Drug Administration for launch of Mavyret medication. This product is an antiviral drug which can be used in treatment of all type of genetoypes of Hepatitis C in pediatric patients.
Key Benefits of the Report
- This study presents the analytical depiction of HCV direct acting antiviral market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the HCV direct acting antiviral market share.
- The current market is quantitatively analyzed to highlight the HCV direct acting antiviral market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the HCV Direct Acting Antiviral Market Report
- Which are the leading players active in the HCV direct acting antiviral market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "HCV direct acting antiviral"?
- What is "HCV direct acting antiviral" market prediction in the future?
- Who are the leading global players in the "HCV direct acting antiviral" market?
- What are the current trends and predicted trends?
- What are the key benefits of the "HCV direct acting antiviral" market report?
HCV Direct Acting Antiviral Market, by Product Type Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Drug Class |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Johnson and Johnson Services, Inc., Genentech, F. Hoffmann-La Roche, AbbVie, Vertex, Gilead Sciences., Merck & Co., Bristol Myers Squibb |
Loading Table Of Content...
